Molecular mechanisms of lymphangiogenesis in health and disease.

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42

Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07

VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98

Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (2003) 3.60

Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol (2003) 3.35

PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev (2005) 3.29

The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46

Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem (2012) 1.93

Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A (2006) 1.81

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J (2010) 1.78

Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.72

Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 1.72

The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem (2004) 1.69

B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol (2003) 1.68

Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer (2011) 1.48

Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology (2009) 1.48

Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater (2012) 1.41

Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res (2008) 1.38

Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol (2003) 1.31

Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer (2008) 1.31

Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer (2007) 1.30

The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med (2002) 1.28

Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am J Pathol (2003) 1.28

VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One (2009) 1.28

Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer. World J Gastroenterol (2011) 1.26

Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol (2004) 1.25

Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. Am J Pathol (2009) 1.23

Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A (2012) 1.23

Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22

Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (2006) 1.21

The role IL-1 in tumor-mediated angiogenesis. Front Physiol (2014) 1.19

SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18

Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol (2010) 1.15

Angiogenesis in the infarcted myocardium. Antioxid Redox Signal (2012) 1.15

A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med (2013) 1.13

Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res (2009) 1.13

Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem (2009) 1.11

Netrin-4 induces lymphangiogenesis in vivo. Blood (2010) 1.10

Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol (2005) 1.09

Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (2013) 1.09

Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog (2009) 1.07

Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. Am J Pathol (2005) 1.05

C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene (2011) 1.05

Double target for tumor mass destruction. J Clin Invest (2003) 1.04

Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol (2014) 0.99

The new era of the lymphatic system: no longer secondary to the blood vascular system. Cold Spring Harb Perspect Med (2012) 0.97

Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol (2009) 0.96

Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells. Neoplasia (2007) 0.94

Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell-endothelium interactions. J Anat (2009) 0.94

The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget (2012) 0.94

Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis. PLoS One (2012) 0.93

Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y Acad Sci (2010) 0.93

The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene (2011) 0.92

Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.92

Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer (2010) 0.92

Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch (2009) 0.92

VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol (2013) 0.91

Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90

Lymphangiogenesis-independent resolution of experimental edema. Am J Physiol Heart Circ Physiol (2010) 0.90

Mechanism of lymph node metastasis in prostate cancer. Future Oncol (2010) 0.90

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther (2009) 0.90

Tyrosine Kinase Receptor Flt/VEGFR Family: Its Characterization Related to Angiogenesis and Cancer. Genes Cancer (2010) 0.90

Altered lymphatic function and architecture in salt-induced hypertension assessed by near-infrared fluorescence imaging. J Biomed Opt (2012) 0.89

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle (2014) 0.88

Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci (2011) 0.87

Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model. Clin Exp Metastasis (2013) 0.87

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. Oncotarget (2013) 0.86

Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal (2013) 0.86

Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res (2010) 0.86

Bone morphogenetic protein 2 signaling negatively modulates lymphatic development in vertebrate embryos. Circ Res (2013) 0.86

CRSBP-1/LYVE-1 ligands disrupt lymphatic intercellular adhesion by inducing tyrosine phosphorylation and internalization of VE-cadherin. J Cell Sci (2011) 0.84

Role of lymphatic vasculature in regional and distant metastases. Microvasc Res (2014) 0.83

b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea (2012) 0.83

Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel) (2013) 0.83

Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. Neoplasia (2005) 0.82

Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours. Int J Exp Pathol (2007) 0.82

Andes virus infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and vascular endothelial growth factor C sensitive. J Virol (2012) 0.82

Attenuation of EGFL7 inhibits human laryngocarcinoma cells growth and invasion. Int J Clin Exp Med (2015) 0.82

Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed Res Int (2014) 0.82

Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol (2016) 0.81

Prognostic Significance of VEGF-C Expression in Patients with Breast Cancer: A Meta-Analysis. Iran J Public Health (2014) 0.81

Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies. J Thyroid Res (2011) 0.81

Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol (2011) 0.80

Lack of lymphatic vessel phenotype in LYVE-1/CD44 double knockout mice. J Cell Physiol (2009) 0.80

Endothelial cell Bcl-2 and lymph node metastasis in patients with oral squamous cell carcinoma. J Oral Pathol Med (2011) 0.80

Interleukin-8: A potent promoter of angiogenesis in gastric cancer. Oncol Lett (2015) 0.79

Co-opting biology to deliver drugs. Biotechnol Bioeng (2014) 0.79

Heparanase 2 Attenuates Head and Neck Tumor Vascularity and Growth. Cancer Res (2016) 0.79

Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. Biomed Res Int (2014) 0.79

sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways. Oncotarget (2015) 0.79

Lymphangiogenesis and Lesion Heterogeneity in Interstitial Lung Diseases. Clin Med Insights Circ Respir Pulm Med (2016) 0.79

Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma. Clin Exp Metastasis (2015) 0.79

Tumor cell intravasation. Am J Physiol Cell Physiol (2016) 0.78

An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis (2013) 0.78

Biomaterial guides for lymphatic endothelial cell alignment and migration. Acta Biomater (2010) 0.78

The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. J Mol Histol (2011) 0.78

Repair of abdominal wall defects in vitro and in vivo using VEGF sustained-release multi-walled carbon nanotubes (MWNT) composite scaffolds. PLoS One (2013) 0.78

Hypoxia and inflammation. N Engl J Med (2011) 7.71

Gene prioritization through genomic data fusion. Nat Biotechnol (2006) 7.48

Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40

uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50

Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19

Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01

Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89

The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84

The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature (2004) 3.77

Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70

A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A (2004) 3.48

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46

VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27

A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08

Role of PFKFB3-driven glycolysis in vessel sprouting. Cell (2013) 3.04

Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92

Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 2.91

VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays (2004) 2.83

Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74

Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64

Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39

CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38

VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37

Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab (2007) 2.35

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26

Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 2.22

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 2.20

VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20

Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci (2008) 2.15

Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov (2009) 2.10

The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09

Regulation of angiogenesis by oxygen and metabolism. Dev Cell (2009) 2.04

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01

Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest (2008) 2.00

Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00

Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98

Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98

Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online (2002) 1.91

Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91

Mechanisms of vessel branching: filopodia on endothelial tip cells lead the way. Arterioscler Thromb Vasc Biol (2009) 1.91

Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89

Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med (2004) 1.89

Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88

Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol (2008) 1.88

Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood (2007) 1.86

Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev (2007) 1.86

The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron (2011) 1.85

A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85

VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res (2003) 1.82

Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res (2003) 1.81

VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med (2003) 1.79

Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 1.77

Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation (2006) 1.76

Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest (2006) 1.75

Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. Arterioscler Thromb Vasc Biol (2011) 1.75

Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol (2011) 1.72

Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest (2004) 1.72

Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int (2004) 1.71

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J (2002) 1.70

Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell (2012) 1.69

Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J (2009) 1.68

Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol (2008) 1.68

Hypoxia-inducible factors 1alpha and 2alpha regulate trophoblast differentiation. Mol Cell Biol (2005) 1.67

Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65

Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology (2010) 1.64

Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol (2008) 1.62

Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62

Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol (2002) 1.59

Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59

Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res (2009) 1.57

Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation (2009) 1.57

Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation (2005) 1.55

Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55

Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods (2008) 1.55

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer (2010) 1.54

Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A (2002) 1.52

Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain (2012) 1.52

Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest (2007) 1.49

Engineering vascularized bone: osteogenic and proangiogenic potential of murine periosteal cells. Stem Cells (2012) 1.49

TRPA1 underlies a sensing mechanism for O2. Nat Chem Biol (2011) 1.47

VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nat Neurosci (2006) 1.46

Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2013) 1.46

Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet (2008) 1.46

Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. J Clin Invest (2006) 1.46

VEGF mediates commissural axon chemoattraction through its receptor Flk1. Neuron (2011) 1.45

Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest (2011) 1.44

The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol (2008) 1.43